Clinical Trials: Page 5
-
jitendrajadhav via Getty Images
Pain drugsTris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing medications, has a good shot at reaching market.
By Jacob Bell • March 6, 2025 -
wildpixel via Getty Images
Deep Dive // State of PlayBlocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research practically overnight.
By Ben Fidler • March 4, 2025 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Jacob Bell/BioPharma Dive
Protagonist says Takeda-partnered drug succeeds in rare blood cancer
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to treat polycythemia vera.
By Ned Pagliarulo • March 3, 2025 -
Michael M. Santiago via Getty Images
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially landscape-changing combinations.”
By Jonathan Gardner • Feb. 24, 2025 -
JHVE Photo via Getty Images
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
By Ned Pagliarulo • Feb. 24, 2025 -
Permission granted by ICON
Sponsored by ICONPartnering for success in early phase clinical development
Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.
Feb. 24, 2025 -
Jose Luis Calvo Martin, Jose Enrique Garcia-Maurino Muzquiz via Getty Images
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including Sarepta Therapeutics’ Elevidys.
By Ben Fidler • Feb. 18, 2025 -
JHVE Photo via Getty Images
Sanofi to take $250M charge on study failure for E. coli vaccine
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.”
By Kristin Jensen • Feb. 13, 2025 -
coldsnowstorm via Getty Images
Obesity drugsNew study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.
By Jonathan Gardner • Feb. 12, 2025 -
magicmine, iStock / Getty Images Plus via Getty Images
Pliant shares collapse as company halts fibrosis drug study
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, but doesn’t yet know what led to their decision.
By Ben Fidler • Feb. 10, 2025 -
hapabapa via Getty Images
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer duration in the new trial.
By Jonathan Gardner • Feb. 5, 2025 -
Honglouwawa via Getty Images
Shares of psychedelics biotech nearly double on depression data
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.
By Jacob Bell • Feb. 3, 2025 -
Jacob Bell/BioPharma Dive
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.
By Jonathan Gardner • Feb. 3, 2025 -
Lark Andrew Balcita via Getty Images
Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of neuroendocrine tumor.
By Ned Pagliarulo • Jan. 28, 2025 -
Dr_Microbe via Getty Images
Akero says MASH drug reverses liver damage in study, doubling shares
Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.
By Ned Pagliarulo • Jan. 27, 2025 -
Sinhyu via Getty Images
Muscle-building drug improves body composition in obesity trial, Veru says
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
By Jonathan Gardner • Jan. 27, 2025 -
Victor Golmer via Getty Images
Novo shares climb on early data for dual-acting obesity drug
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.
By Jonathan Gardner • Jan. 24, 2025 -
cagkansayin via Getty Images
Immune resetIGM’s autoimmune pivot backfires as top drug disappoints in testing
The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.
By Ben Fidler • Jan. 9, 2025 -
Sean Gallup via Getty Images
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.
By Delilah Alvarado • Jan. 9, 2025 -
Douglas Cliff via Getty Images
Metsera reveals data supporting long-acting obesity shot
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug as a future threat to weight loss medicines from Novo Nordisk and Eli Lilly.
By Jonathan Gardner • Jan. 7, 2025 -
Mario Tama via Getty Images
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.
By Ned Pagliarulo • Jan. 7, 2025 -
koto_feja via Getty Images
ALS drug developmentALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
By Jacob Bell • Jan. 7, 2025 -
image_jungle via Getty Images
Neumora plummets on depression drug data
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.”
By Jacob Bell • Jan. 2, 2025 -
Kendall Davis/BioPharma Dive
Tracker10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and AATD headline a series of study results that could give the biotechnology sector a boost.
By BioPharma Dive staff • Updated June 30, 2025 -
Courtesy of Novo Nordisk
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
By Jonathan Gardner • Updated Dec. 20, 2024
Previous
